Abstract
Preparation of large enough quantities of purified, chemically characterized biological response modifiers (BRMs) has required years of preparative and analytic studies leading to isolation and characterization of biologically active, pure peptides. Prior to the presently limited use of such peptides, phase I studies were carried out to determine biological effects of more complex preparations in patients, as in the case of human leukocyte interferon (Strander et al., 1973) and thymosin fraction 5 (Costanzi et al., 1977). Complex lymphokine fractions have been used for inducing local skin inflammatory reactions (Papermaster et al., 1976) and to treat dermal tumor lesions by direct intralesional injection (Paradinas et al., 1982) and also have been administered intravenously by Dumonde et al. (1981) to patients with disseminated cancer at low to moderate doses [1–2 ml delivering a total of 70 mg protein (Organon preparation)] and roughly equivalent to our unitage of between 200 and 500 units (Paradinas et al., 1982).
Pamela A. Dunn died February 9, 1983
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Costanzi, J. J., Gagliano, R., Delaney, F., Harris, N., Thurman, G., Sakai, H., Goldstein, A., Loukas, D., Cohen, G., and Thomson, P. D., 1977, The effect of thymosin on patients with disseminated malignancies, Cancer 40:14–19.
David, J. R., 1975, Macrophage activation by lymphocyte mediators, Fed. Proc. 34:1730–1735.
Dumonde, D. C., Paradinas, F., Pulley, M., Southcott, B., O’Connell, D., Robinson M., and den Hollander, F., 1981, A histological study of intradermal and intralesional injection of human lymphoid cell line lymphokine (LCL-LK) in patients with advanced cancer, J. Clin. Hematol. Oncol. 11:130.
Dunn, P. A., Eaton, W. R., Lopatin, E., Tyrer, H., McEntire, J. E., Papermaster, B. W., Miller, A., and Vosika, G., 1982, Macrophage activation by lymphokine factors (MAF) as measured by phagocytosis, metabolic products, and tumor cell cytotoxicity: Correlation of multiparameter functional assays, in: Human Lymphokines: The Biological Immune Response Modifiers (A. Khan and N. O. Hill, eds.), pp. 67–82, Academic Press, New York.
Fidler, I. J., Darnell, J. H., and Budman, M. B., 1976, In vitro activation of mouse macrophage by rat lymphocyte mediators, J. Immunol. 117:666–673.
Goldstein, A. L., Low, T. L. K., Thurman, G. B., Zatz, M. M., McClure, J. E., Hall, N., and Hu, S. K., 1981, Recent developments in the chemistry, biology and clinical applications of thymosin, in: Cellular Responses to Molecular Modulators (L. W. Mozes, J. Schultz, W. A. Scott, and R. Werner, eds.), pp 237–247, Academic Press, New York.
Kniep, E. M., Domzis, W., Lohmann-Matthes, M. L., and Kickhofen, B., 1981, Partial purification and chemical characterization of macrophage cytotoxicity factor (MCF, MAF) and its separation from migration inhibitory factor (MIF), J. Immunol. 127:417–422.
McDaniel, M. C., 1980, Human macrophage activation factors. I. Multiple molecular species of MAF produced by a human lymphoid cell line, Inflammation 4:125–135.
McEntire, J. E., Dunn, P. A., Gehrke, C. W., and Papermaster, B. W., 1981, Isolation and purification of an acid-soluble polypeptide with lymphokine properties from a human lymphoblastoid cell line, in: Lymphokines and Thymic Hormones: Their Potential Utilization in Cancer Therapeutics (A. L. Goldstein and M. A. Chirigos, eds.) pp. 109–119, Raven Press, New York.
Nathan, C.F., Karnovsky, M. L., and David, J. R., 1971, Alteration of macrophage functions by mediators from lymphocytes, J. Exp. Med. 133:1356–1376.
Pace, J. L., Taffet, S. M., and Russell, S. W., 1981, Endotoxin in eliciting agents affects activation of mouse macrophages for tumor killing, J. Reticuloendothel. Soc. 30:15–21.
Papermaster, B. W., Holterman, O. A., Klein, E., Parmett, S., Dobkin, D., Laudico, R., and Djerassi, I., 1976, Preliminary observations on tumor regressions induced by local administration of a lymphoid cell culture supernatant fraction in patients with cutaneous metastatic lesions, Clin. Immunol. Immunopathol. 5:48–59.
Paradinas, F. J., Southcott, B. ML, O’Connell, D., den Hollander, F., Schuurs, A. H., Pulley, M. S., and Dumonde, D. C., 1982, Changes induced by local injection of human lymphoid cell lymphokine into dermal metastases of breast carcinoma: A light and electron microscopial study, J. Pathol. 138:309–323.
Pestka, S., Maeda, S., Hobbs, D. S., Levy, W. P., McCandliss, R., Stein, S., Moschera, J., and Staehelin T., 1981, The human interferon, in: Cellular Responses to Molecular Modulators (L. W. Mozes, J. Schultz, W. A. Scott, and R. Werner, eds.), pp. 455–489, Academic Press, New York.
Piessens, W. F., Churchill, W. H., Jr., and David J. R., 1975, Macrophages activated in vitro with lymphocyte mediators kill neoplastic but not normal cell, J. Immunol. 114:293–299.
Rios, A., Hersh, E. M., Gutterman, J. U., Mavligit, G. M., Schimek, H., McEntire, J. E., and Papermaster, B. W., 1979, The use of a leukocyte cell line culture supernatant for skin reaction testing in malignant melanoma. Cancer 44:1615–1621.
Ruco, L. P., and Meltzer, M. S., 1978, Macrophage activation for tumor cytotoxicity: Development of macrophage cytotoxic activity requires completion of a sequence of short-lived intermediary reactions, J. Immunol. 121:2035–2041.
Sama, G., Figlin, R., and McCarthy, S., 1983, Phase I study of Wellferon (human lymphoblastoid α-interferon) as cancer therapy: Clinical results, J. Biol. Resp. Modif. 2:187–195.
Sorg, C., 1982, Heterogeneity of macrophages in response to lymphokines and other signals, Mol. Immunol. 19:1275–1278.
Strander, H. K., Cantell, K., Carlstrom, G., and Jakobson, P. A., 1973, Clinical and laboratory investigations on man: Systemic administration of the potent interferon to man, J. Natl. Cancer Inst. 51:733–740.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Plenum Press, New York
About this chapter
Cite this chapter
Papermaster, B.W. et al. (1984). Phase I Trial of Intravenous Lymphokine MAF. In: Goldstein, A.L. (eds) Thymic Hormones and Lymphokines. GWUMC Department of Biochemistry Annual Spring Symposia. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4745-3_38
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4745-3_38
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4747-7
Online ISBN: 978-1-4684-4745-3
eBook Packages: Springer Book Archive